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Many neuromuscular conditions are characterized by an exagger-
ated exercise-induced fatigue response that is disproportionate to
activity level. This fatigue is not necessarily correlated with greater
central or peripheral fatigue in patients1, and some patients
experience severe fatigue without any demonstrable somatic dis-
ease2. Except in myopathies that are due to specific metabolic
defects, the mechanism underlying this type of fatigue remains
unknown2. With no treatment available, this form of inactivity
is a major determinant of disability3. Here we show, using mouse
models, that this exaggerated fatigue response is distinct from a
loss in specific force production by muscle, and that sarcolemma-
localized signalling by neuronal nitric oxide synthase (nNOS) in
skeletal muscle is required to maintain activity after mild exercise.
We show that nNOS-null mice do not have muscle pathology and
have no loss of muscle-specific force after exercise but do display
this exaggerated fatigue response to mild exercise. In mouse mod-
els of nNOS mislocalization from the sarcolemma, prolonged inac-
tivity was only relieved by pharmacologically enhancing the cGMP
signal that results from muscle nNOS activation during the nitric
oxide signalling response to mild exercise. Our findings suggest
that the mechanism underlying the exaggerated fatigue response
to mild exercise is a lack of contraction-induced signalling from
sarcolemma-localized nNOS, which decreases cGMP-mediated
vasomodulation in the vessels that supply active muscle after mild
exercise. Sarcolemmal nNOS staining was decreased in patient
biopsies from a large number of distinct myopathies, suggesting
a common mechanism of fatigue. Our results suggest that patients
with an exaggerated fatigue response to mild exercise would show
clinical improvement in response to treatment strategies aimed at
improving exercise-induced signalling.
To understand the molecular basis of the exercise-induced fatigue
response, we studied genetically defined mouse models. We designed
an integrative in vivo assay to test conscious mice, subjecting the mice
to brief low-speed treadmill exercise followed by testing in an open-
field activity chamber (see Methods). We first assessed two
dystrophic mouse lines, mdx (model for Duchenne muscular
dystrophy)4 and Sgca-null (model for limb-girdle muscular dys-
trophy type 2D that is deficient for the gene encoding a-sarcoglycan
(Sgca))5. In the absence of previous exercise, activity in these mice
was indistinguishable from that of wild-type mice (Fig. 1a, b, and
Supplementary Videos 1a–d). After a single trial of mild exercise,
significant differences were observed (Fig. 1a, b, and Supple-
mentary Videos 2a–d): the mdx and Sgca-null mice showed a signifi-
cant decrease in vertical activity.
The decrease in vertical activity among mdx and Sgca-null mice did
not correlate with differences in extensor digitorum longus (EDL)-
specific force measurements relative to those taken in C57BL/6 mice
before exercise (Fig. 1c). Moreover, Sgca-null mice do not develop
brain, heart or vascular pathology6, and they have muscle-force
values similar to those of control mice7. Therefore, neither cardiac
deficiency nor an inability to produce force was the cause of the post-
exercise inactivity in the Sgca-null mice. Because inflammation is a
feature of dystrophinopathy4, chronic fatigue is associated with mus-
cle pain, and chronic pain is associated with fatigue8, we treated mdx
mice with either deflazacort or ibuprofen. However, neither treat-
ment resulted in improved post-exercise activity (Fig. 1d), suggesting
that the inactivity occurring immediately after mild exercise in mdx
mice was not due to inflammation or pain. Overall, the results of our
exercise–activity assay implied that the exaggerated fatigue response
in these mice was not attributable to cardiac deficiency, inflam-
mation, pain or lack of muscle force.
To test whether the exercise-induced inactivity in the mdx and
Sgca-null mice was due to the genetically determined structural
defect in muscle, we assayed two mouse models in which the muscle
pathology related to the specific dystrophin glycoprotein complex
(DGC) defect is rescued—microdystrophin/mdx and MCKeSG/
Sgca-null. In microdystrophin/mdx mice (a model for mild Becker
muscular dystrophy9—the DGC has a mutated but functional dys-
trophin), microdystrophin is expressed in mdx mouse muscle. In the
MCKeSG/Sgca-null mice, e-sarcoglycan is expressed in mouse mus-
cle that is deficient for Sgca (Supplementary Fig. 1). Neither rescue
strain showed pathological signs of muscular dystrophy, and the
skeletal muscle DGC of both was recovered at the biochemical, struc-
tural and functional levels (refs 9, 10 and Supplementary Figs 1 and
2).
Despite having a structurally intact skeletal muscle DGC, micro-
dystrophin/mdx mice experience a substantial decrease in activity
after mild exercise, like their mdx littermates (Fig. 1e). Because
patients with Becker muscular dystrophy show profound fatigue after
light exertion11, and loss of sarcolemma-localized nNOS serves as a
diagnostic indicator of some forms of Becker muscular dystrophy12, a
possible reason for the post-exercise inactivity is a loss of sarco-
lemma-localized nNOS. To test this possibility we probed for
nNOS localization in microdystrophin/mdx skeletal muscle and
found that the DGC generated in this rescue strain failed to recruit
nNOS to the sarcolemma (Fig. 1e, inset). These data are in agreement
with recent reports on microdystrophin expression in dystrophin-
deficient mouse models13. Moreover, the data suggest that exercise-
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induced inactivity in the microdystrophin/mdx mice is not caused
directly by a structurally defective muscle DGC, and that loss of
sarcolemmal nNOS does not negatively affect muscle contractility.
Thus, sarcolemmal nNOS seems to act at the level of post-exercise
activity.
In contrast to the microdystrophin/mdx mice, MCKeSG/Sgca-null
mice have structurally intact DGC in the brain and the vasculature,
but express e-sarcoglycan instead of a-sarcoglycan in the DGC of
muscle. Our exercise–activity assay showed that post-exercise activity
in the MCKeSG/Sgca-null mice was substantially decreased relative
to that in C57BL/6 mice but similar to that in Sgca-null and mdx mice
(Fig. 1b, f). Because the microdystrophin-containing DGC failed to
recruit nNOS, we speculated that the MCKeSG/Sgca-null mice would
also fail to localize nNOS to the sarcolemma. Indeed, although total
nNOS levels in muscle homogenates from MCKeSG/Sgca-null mice
were similar to those in the wild type, nNOS from the rescue model
failed to purify together with the e-sarcoglycan-containing DGC in
the membrane preparation (Fig. 1f, inset). Taken together, these
results are compatible with the notion that the exaggerated fatigue
response is not directly related to a structurally defective muscle DGC
or to muscle weakness, but rather to a failure in the sarcolemmal
localization of nNOS.
Because sarcolemma-localized nNOS is crucial for maintaining
vasomodulation to contracting muscles14, we tested whether com-
munication from skeletal muscle to the local blood supply is deficient
after mild exercise by perfusing MCKeSG/Sgca-null mouse arteries
before or after exercise with Microfil and examined the skeletal mus-
cle vasculature (Fig. 1g). We identified vascular narrowings of vari-
ous lengths along the arteries that feed the skeletal muscles in the
post-exercise samples only, and also noted the lack of perfusion of
capillaries. The mdx and microdystrophin/mdx mice similarly
showed skeletal muscle vascular narrowings only after exercise and
also a lack of perfusion of capillaries (Supplementary Fig. 3c and data
not shown). This phenotype is consistent with inefficient contrac-
tion-induced muscle nNOS signalling to local blood vessels. Overall,
these data imply that loss of sarcolemma-localized nNOS causes
deficient exercise-induced vasomodulation in skeletal muscle, and
that these lead to prolonged inactivity after mild exercise.
To directly examine the contribution of NO generated by endothe-
lial NOS (eNOS) or nNOS to the exaggerated fatigue response, we
tested both nNOS-null and eNOS-null mice in our exercise–activity
assay. Mice deficient for nNOS express normal levels of the DGC
components at the sarcolemma and have histologically normal mus-
cle15–17. Reports suggest that both mouse strains have defective vaso-
regulation18,19; however, mdx and nNOS-null mice have a normal
a-adrenergic vasoconstrictive response to exercise20. Vertical pre-
exercise activities were similar in eNOS-null, nNOS-null and
C57BL/6 mice, suggesting that the loss of either NOS does not affect
mouse activity (Fig. 2a). After exercise, however, nNOS-null vertical
activity decreased significantly (Fig. 2a). Serum creatine kinase levels
before and after exercise for each of the NOS-null mice were similar
to those in C57BL/6 mice and low compared with mdx mice (Fig. 2b),
and there were no signs of muscle pathology in sections from nNOS-
null quadriceps muscle (Supplementary Fig. 4b), suggesting that
muscle damage and necrosis were not the causes of the post-exercise
inactivity. We then tested whether post-exercise muscle contractility
affected the ability of C57BL/6 and nNOS-null skeletal muscle to
produce force after mild exercise. We found that the specific force
of EDL muscles after exercise was not significantly affected in nNOS-
null muscle in comparison with C57BL/6 muscle (Supplementary
Fig. 4c). Because lack of muscle contractility was not causing the
inactivity in the nNOS-null mice after exercise, we checked whether
NOS-null mice had post-exercise skeletal muscle vascular narrowings
and lack of capillary perfusion similar to those in the dystrophic and
rescue mice. Microfil perfusion of arteries from NOS-null mice
before and after exercise revealed the lack of capillary perfusion
and also the presence of vascular narrowings only in post-exercise
nNOS-null skeletal muscle (Fig. 2c). We also found that treating
wild-type mice with either the nNOS-specific inhibitor 3-bromo-7-
nitroindazole or the vasoconstrictor sarafotoxin 6c caused post-exer-
cise inactivity (Fig. 2d). These findings suggest that a deficiency of
sarcolemma-localized nNOS causes exercise-induced narrowing of
the vasculature that feeds active muscles after exercise, thereby pro-
moting prolonged inactivity after mild exercise.
To test whether the vascular effect on post-exercise activity











































































































































Figure 1 | Loss of sarcolemma-localized nNOS leads to skeletal muscle
vascular narrowings, decreased capillary perfusion and an exaggerated
fatigue response after mild exercise in dystrophic and non-dystrophic
mouse models. a, Representative vertical activity tracings of zone maps for
C57BL/10 and mdx mice before and after exercise. b, Quantified vertical
activity before (filled columns) and after (open columns) exercise for
C57BL/10, C57BL/6, mdx and Sgca-null mouse strains (n 5 6 for each
strain). Asterisk, P 5 0.012. c, EDL muscle-specific force measurements
from C57BL/6 (n 5 6), mdx (n 5 4) and Sgca-null (n 5 4) mice. Asterisk,
P , 0.05. d, Pre-exercise (filled columns) and post-exercise (open columns)
vertical activity in untreated (n 5 7) and anti-inflammatory treated mdx
mice, acutely (n 5 4) or chronically (n 5 4) with deflazacort or acutely with
ibuprofen (n 5 5). Asterisk, P , 0.003. e, Left panel: quantified pre-exercise
(filled columns) and post-exercise (open columns) vertical activity for
microdystrophin/mdx mice (n 5 6) and their mdx littermates (n 5 4).
Asterisk, P 5 0.005; two asterisks, P , 0.0001. The right panels show
representative immunofluorescence images of nNOS detection in the
gastrocnemius muscles from C57BL/6 and microdystrophin/mdx mice.
f, Quantified pre-exercise (filled columns) and post-exercise (open columns)
vertical activity for MCKeSG/Sgca-null mice (n 5 6) and their Sgca-null
littermates (n 5 6). Asterisk, P , 0.0001. Inset: immunoblot detection of
total nNOS from homogenates (hom), and crude skeletal muscle
membranes (cm). g, Representative Microfil image of skeletal muscle vessels
of MCKeSG/Sgca-null mice after exercise—large arrowheads mark extended
areas of vascular narrowing; the small arrow marks a shorter stretch of radial
vascular narrowing. Error bars indicate s.e.m.
LETTERS NATURE | Vol 456 | 27 November 2008
512
 ©2008 Macmillan Publishers Limited. All rights reserved
sarcolemmal nNOS signalling for decreasing vasoconstriction by
treating mdx mice with a panel of pharmacological agents that pro-
mote vasodilation; we found that the exaggerated fatigue response
was alleviated only by treatment with a phosphodiesterase (PDE) 5A
inhibitor (Supplementary Fig. 6), suggesting that the fatigue that we
saw depended on cGMP, which acts downstream of NO production.
PDE activity in mdx mice is 2–6-fold higher than in C57BL/10 mice21,
which is consistent with the elevated PDE activity in human muscular
disorders18,21,22. We treated nNOS-null, MCKeSG/Sgca-null and mdx
mice with PDE5A inhibitors and tested them in our exercise–activity
assay; we found that the treated MCKeSG/Sgca-null and mdx mice
showed an increase in post-exercise activity (Fig. 2e and
Supplementary Fig. 7a–d). Because inhibition of PDE5A had no
effect on activity before exercise, our results suggest that PDE5A
inhibition is alleviating the exaggerated fatigue response by enhan-
cing the cGMP signal produced by contraction-induced nNOS
stimulation. Although downstream effectors of cGMP are numerous
and divergent23, the half-life of cGMP can be affected by the activity of
PDE5A. Our data indicate that the elevated PDE activity in extracts
from mdx mice could be PDE5A activity, and that PDE activity could
also be elevated in the rescue mouse models we tested.
Our data suggest that the local resistance of arterioles that perfuse
sarcolemmal nNOS-deficient muscles increases during exercise and
that the lack of activity after mild exercise will lead to muscle oedema.
We examined blood flow before and after exercise with laser Doppler
imaging and found that blood flow in mdx mice failed to increase as it
did in C57BL/6 mice (Fig. 3a and Supplementary Fig. 7a), but treat-
ment of mdx mice with a PDE5A inhibitor alleviated this defect
(Fig. 3b) and increased muscle capillary perfusion (Fig. 3c). Given
that insufficient relief of local vasoconstriction in active muscles can
lead to muscle oedema24, and that boys with Duchenne muscular
dystrophy show muscle oedema25, we looked for changes in water
compartmentalization and dynamics in the hindleg muscles of
nNOS-null, C57BL/10 and mdx mice before and after exercise by
using spin–spin relaxation time (T2)-magnetic resonance imaging.
The nNOS-null mice did not have muscle damage or loss of contract-
ility after exercise (Fig. 2b and Supplementary Fig. 4b, c), nor did they
have muscle oedema (Supplementary Fig. 8a), suggesting that their
lack of muscle damage prevents water accumulation in the tissue.
Similarly, C57BL/10 mice showed little to no oedema in hindleg





























Figure 3 | Treatment with PDE5A inhibitor improves exercised-induced
vasomodulation and decreases exercise-induced oedema in mdx mice.
a, Representative images of coronal laser Doppler analysis of blood flow in
mdx mice before (top) and after (bottom) exercise (n 5 3). b, Coronal laser
Doppler analysis of blood flow in mdx mice, before (top) and after (bottom)
exercise, treated with PDE5A inhibitor before exercise (n 5 3).
c, Representative Microfil image of quadriceps skeletal muscle arteries after
exercise from mdx mice treated with PDE5A inhibitor before exercise (n 5 3;
scale bar, 100mm). d, e, Representative axial views, by magnetic resonance
imaging, of mdx hindlimb muscles before (left) and after (right) exercise
(n 5 5) (d) and hindlimb muscles after exercise of mdx mice treated with
PDE5A inhibitor before exercise (n 5 5) (e). White arrowheads mark areas
of increased water compartmentalization. f, Percentage muscle oedema area
before (filled columns) and after (open columns) exercise, and with or
without treatment with PDE5A inhibitor, in mdx mice compared with that
of the wild type. (Wild type and mdx, n 5 3; mdx plus PDE5A inhibitor,


















































































Figure 2 | Enhancing the cGMP signal resulting from muscle nNOS
activation decreases the exaggerated fatigue response to mild exercise.
a, Comparison of vertical activity before (filled columns) and after (open
columns) exercise between C57BL/6, eNOS-null and nNOS-null mice (n 5 6
for each). Two asterisks, P , 0.001. b, Serum creatine kinase (CK) levels
before (filled columns) and after (open columns) exercise in C57BL/6
(n 5 6), eNOS-null (n 5 4) and nNOS-null (n 5 6) mice, compared with
mdx mice (n 5 6). c, Representative Microfil image of nNOS-null quadriceps
skeletal muscle arteries after exercise—the large arrowhead marks the
extended area of vascular narrowing; small arrows mark shorter areas of
radial vascular narrowing. Scale bar, 100mm. d, Pre-exercise (filled columns)
and post-exercise (open columns) vertical activities in untreated wild-type
(C57BL/6 and C57BL/10) mice (n 5 4), compared with 3-B-7-Ni-treated
wild-type mice (n 5 3) and sarafotoxin-treated wild-type mice (n 5 4).
Asterisk, P , 0.01. e, Quantified pre-exercise (filled columns) and post-
exercise (open columns) activity with and without treatment with PDE5A
inhibitor, in nNOS-null (n 5 4), MCKeSG/Sgca-null (n 5 4) and mdx mice
(n 5 6). Asterisk, P , 0.0001. Pre-exercise and post-exercise vertical activity
error bars are s.e.m.
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Supplementary Fig. 8b). However, hindleg muscles of mdx mice
consistently showed significant changes in tissue hydration after
exercise (25.0 6 2.45% (mean 6 s.e.m.)) (Fig. 3d, f) that were indi-
cative of exercise-induced muscle oedema. The water accumulation
observed in the mdx muscles is probably due to a combination of the
increased local resistance in the arterioles that feed the active leg
muscles and of muscle fibre fragility and damage. We also consis-
tently found that treatment with PDE5A inhibitor significantly
decreased exercise-induced muscle oedema in mdx mice
(3.99 6 0.82% (mean 6 s.e.m.); Fig. 3e, f). Overall, our data imply
that treatment with PDE5A inhibitor can relieve the post-exercise
inactivity by normalizing PDE activity, thereby allowing the available
NO derived from muscle nNOS to signal for cGMP-dependent vaso-
dilation in active muscle; treatment with PDE5A inhibitor decreases
muscle damage in mdx mice by improving modulation of vascular
activity in active muscle, thus preventing muscle oedema from
exacerbating the muscle damage that occurs during the contraction
of dystrophic muscle.
Because more than 60% of all patients with neuromuscular disease
suffer from severe fatigue2, we tested for nNOS localization to the
sarcolemma in biopsies of patients representing different myopathic
disorders (Fig. 4, Supplementary Fig. 9 and Supplementary Table 1).
In most myopathic biopsies assessed, sarcolemma-localized nNOS
was either reduced or not detected, implying that many myopathic
disorders may share a mechanism that results in severe exercise-
induced fatigue. Although increased fatigability inevitably occurs in
patients with muscle weakness1, our mouse data imply that the exer-
cise-induced inactivity is distinct from muscle weakness and that loss
of sarcolemma-localized nNOS leads to an exaggerated fatigue res-
ponse to mild exercise.
Our mouse data show that decreased or mislocalized skeletal mus-
cle nNOS exacerbates the fatigue experienced after mild exercise
because the normal contraction-induced cGMP-dependent attenu-
ation of local vasoconstriction fails to occur, and that this failure
causes vascular narrowing in muscles after exercise. In addition, our
data from mdx mice suggest that, as a result of nNOS mislocalization
and increased PDE activity10,18,21, signalling for increased vasodilation
to active muscle is deficient, causing muscle oedema. This, in turn,
contributes to increased muscle damage as well as profound post-
exercise debility. Although the exact mechanism that leads to the
inactivity after mild exercise has not been reduced to a single begin-
ning and end pathway, our data suggest that contraction-induced
cGMP-dependent attenuation of local vasoconstriction is pivotal in
this mechanism. These findings could lead to a better understanding
of muscle fatigue under other physiological conditions in which mus-
cle nNOS expression, localization or activity is affected.
METHODS SUMMARY
Mouse models. Animal care and procedures were approved and performed in
accordance with the standards set forth by the National Institutes of Health and
the University of Iowa Animal Care and Use Committee.
Treadmill exercise and activity monitoring. Animals were mildly exercised
with an adjustable variable-speed belt treadmill from AccuPacer. Activity based
on ambulatory behaviour was assessed in an open-field test.
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diseases. Representative immunofluorescent staining in various human
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limb-girdle muscular dystrophy (LGMD); in two congenital muscular
dystrophies (CMD) caused by mutations in extracellular matrix proteins
(Ullrich CMD (UCMD), collagen VI and merosin-deficient CMD (MDC1A).
Asterisks mark the same muscle fibres in some of the adjacent panels. Scale
bar, 100mm.
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